This is the login page for PHARMA JAPAN WEB subscribers. PHARMA JAPAN WEB offers excerpts of some articles for free, but paid subscription is required to read full articles.

Today's Headlines RSS

BUSINESS

AbbVie Hopes to Make Humira Major Drug for Biologics-Naïve Patients: President

AbbVie Inc.’s Japan arm AbbVie G.K. will work to increase the use of its rheumatoid arthritis treatment Humira (adalimumab) in patients who have never been treated with biologics, the president ... > Read full story
REGULATORY
Revised PAL Mandating Submission of Package Inserts to Minister Will Take Effect on Nov 25 (Jul.29)
REGULATORY
Govt Thought TPP Talks Would Be Wrapped Up Sooner: Official (Jul.29)
REGULATORY
PAFSC’s Second Committee to Discuss Kyowa Kirin’s Long-Acting G-CSF Drug Pegfilgrastim on August 8 (Jul.29)
BUSINESS
Meiji Seika Pharma Licenses Opalmon from Ono for Its Commercialization in Thailand and Indonesia (Jul.29)
REGULATORY
Editor’s Pick: Five Healthcare News Headlines for July14 - July 25 (Jul.28)
> More Latest News

Photosmore

  
Japan OKs Guidelines for FY2015 Budget Requests, Natural Rise of 830 Billion Yen in Social Security Costs (Jul.28)JPMA President Hints at Adoption of Unified System to Disclose Fees Paid to Doctors Next Year (Jul.25)With Series of Antidiabetics on the Way, Prioritization Will Be a Challenge: Lilly Japan Diabetes Head (Jul.25)
  
Jiangsu Hengrui Medicine of China Establishes Japanese Subsidiary; Aims for Sales of 10 Billion Yen by 2022 (Jul.24)Kampo Manufacturers Group Names Tsumura President as New Chairman (Jul.24)Research Lab for High-Value Generics Goes Live: Kobayashi Kako (Jul.23)

News Categories

REGULATORY
   Revised PAL Mandating Submission of Package Inserts to Minister Will Take Effect on Nov 25(Jul.29)
   Govt Thought TPP Talks Would Be Wrapped Up Sooner: Official(Jul.29)
   PAFSC’s Second Committee to Discuss Kyowa Kirin’s Long-Acting G-CSF Drug Pegfilgrastim on August 8(Jul.29)
BUSINESS
   Meiji Seika Pharma Licenses Opalmon from Ono for Its Commercialization in Thailand and Indonesia(Jul.29)
   AbbVie Hopes to Make Humira Major Drug for Biologics-Naïve Patients: President(Jul.28)
   New Guidelines for Investigator-Led Trials to Take Effect at August-End: Novartis Japan(Jul.28)
ORGANIZATION
   JPMA President Hints at Adoption of Unified System to Disclose Fees Paid to Doctors Next Year(Jul.25)
   Kampo Manufacturers Group Names Tsumura President as New Chairman(Jul.24)
   Number of Drug Reps Rebounds to 65,752 in FY2013, Buoyed by Major Product Debuts(Jul.23)
ACADEMIA
   Chiba University Weighs Asking University of Tokyo to Punish VART Chief Investigator(Jul.16)
   Chiba Univ. Finds Dropout Rates of 60-80% in Secondary Endpoints, Raps VART Study as “Absolutely Unreliable”(Jul.16)
   60% of Pharmacists Recognize Authorized Generics: Survey(Jul.15)

Commentary

Competition Fuels Personalized Medicine Market, First-Line Positions Eyed for Xalkori, Alecensa

Lexicon

Japan-Version NIH Initiative:
日本版NIH構想

The Column

Taking Pride in Small Things Makes Big Things Possible

Archives

Health Minister Calls for Strict Compliance with Transparency Guidelines(Jul.28)
New Guidelines for Investigator-Led Trials to Take Effect at August-End: Novartis Japan(Jul.28)
Japan OKs Guidelines for FY2015 Budget Requests, Natural Rise of 830 Billion Yen in Social Security Costs(Jul.28)
Januvia Ranked No.1 in GP Market in June: Anterio’s “Mind Share” Ranking(Jul.28)
PDMA to Issue Practical Notification on Submission of Electronic Applications for Approval Next January at Earliest(Jul.28)

Most Read

1.
MHLW Suggests R...
2.
Cabinet Approve...
3.
Ex-Novartis Emp...
4.
JPMA President ...
5.
Ministry Panel ...

News Calendar